Novartis to Invest More Than $100 Million to Research, Develop Antimalarials
April 17 2018 - 2:06AM
Dow Jones News
By Pietro Lombardi
Novartis AG (NOVN.EB) said Tuesday that it will invest more than
$100 million in the next five years in the research and development
of the next-generation antimalarials.
The investment will focus on treatments to tackle resistance to
antimalarials currently in use.
"Resistance to treatment presents the biggest threat to the
incredible progress that has been made in the fight against malaria
in the past 20 years. We cannot afford to wait; this is why we are
committing to advance the research and development of
next-generation treatments," said Chief Executive Vas
Narasimhan.
The company's also said it will work to expand access to
pediatric antimalarials and will help implement programs to
reinforce health-care systems in four sub-Saharan countries.
Write to Pietro Lombardi at pietro.lombardi@dowjones.com
(END) Dow Jones Newswires
April 17, 2018 01:51 ET (05:51 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Novartis (NYSE:NVS)
Historical Stock Chart
From Sep 2023 to Sep 2024